Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Chemours, Lowers Price Target to $33

Morgan Stanley Maintains Equal-Weight on Chemours, Lowers Price Target to $33

Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $41 to $33.

October 25, 2022

1 minute read

Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $41 to $33.

The Latest Analyst Ratings for Lantheus Holdings

November 30, 10:00 AM

Within the last quarter, Lantheus Holdings (NASDAQ:LNTH) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

May 13, 5:08 PM

Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.

October 24, 4:44 PM

INVO BioScience Inc (NASDAQ: INVO) shares traded lower on Tuesday.

November 3, 4:30 AM

Keybanc analyst Todd Fowler maintains C.H. Robinson Worldwide (NASDAQ:CHRW) with a Overweight and lowers the price target from $135 to $120.